Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

(2019) Francesco Panza et al.   Nature Reviews Neurology

Toward a Glutamate Hypothesis of Frontotemporal Dementia

(2019) Alberto Benussi et al.   Frontiers in Neuroscience

Disease-modifying therapies for tauopathies: agents in the pipeline

(2019) Francesco Panza et al.   Expert Review of Neurotherapeutics

An update on genetic frontotemporal dementia

(2019) Caroline V. Greaves et al.   JOURNAL OF NEUROLOGY

Precision Medicine for Frontotemporal Dementia

(2019) Mu-N Liu et al.   Frontiers in Psychiatry

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

(2019) Adam L Boxer et al.   LANCET NEUROLOGY

Neuroinflammation in frontotemporal dementia

(2019) Fiona Bright et al.   Nature Reviews Neurology

Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy

(2019) Raygene Martier et al.   Molecular Therapy-Nucleic Acids

Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD

(2019) Thomas J. Hedl et al.   Frontiers in Neuroscience

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome

(2019) Richard M. Tsai et al.   JAMA Neurology

Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases

(2018) Inga Zerr et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Autoimmunity and Frontotemporal Dementia

(2018) Antonella Alberici et al.   Current Alzheimer Research

Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder

(2018) Madia Lozupone et al.   EXPERT OPINION ON PHARMACOTHERAPY

Progranulin as a therapeutic target for dementia

(2018) Daniela Galimberti et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Plasma tau is increased in frontotemporal dementia

(2018) Martha S Foiani et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders

(2018) Katrin Augustin et al.   LANCET NEUROLOGY

ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function

(2018) Martina de Majo et al.   NEUROBIOLOGY OF AGING

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum

(2018) Lieke H.H. Meeter et al.   NEUROLOGY

A language-based sum score for the course and therapeutic intervention in primary progressive aphasia

(2018) Elisa Semler et al.   Alzheimers Research & Therapy

CSF Biomarkers of Neurodegeneration in Progressive Non-fluent Aphasia and Other Forms of Frontotemporal Dementia: Clues for Pathomechanisms?

(2018) Peter Körtvelyessy et al.   Frontiers in Neurology

Memantine in Behavioral Variant Frontotemporal Dementia: Negative Results

(2018) Martine Vercelletto et al.   JOURNAL OF ALZHEIMERS DISEASE

N-terminal Truncation of Microtubule Associated Protein Tau Dysregulates its Cellular Localization

(2018) Kristina Paholikova et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory

(2018) Peter A. Ljubenkov et al.   Annals of Clinical and Translational Neurology

Therapeutic trial design for frontotemporal dementia and related disorders

(2018) Philippe Desmarais et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Review: Neuropathology of non-tau frontotemporal lobar degeneration

(2018) M. Neumann et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review

(2018) Vincenzo Solfrizzi et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

(2018) Petr Novak et al.   Alzheimers Research & Therapy

Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials

(2018) Adam M Staffaroni et al.   BRAIN

New routes in frontotemporal dementia drug discovery

(2017) Laura De Conti et al.   Expert Opinion on Drug Discovery

Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review

(2017) Massimiliano Buoli et al.   JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY

Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology

(2017) John T O’Brien et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Anti-tau vaccine in Alzheimer's disease: a tentative step

(2017) Francesco Panza et al.   LANCET NEUROLOGY

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

(2017) Nicholas B. Hastings et al.   Molecular Neurodegeneration

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

(2017) Günter U. Höglinger et al.   MOVEMENT DISORDERS

A clinicopathological approach to the diagnosis of dementia

(2017) Fanny M. Elahi et al.   Nature Reviews Neurology

TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics

(2017) Ian R. Mackenzie et al.   NEURON

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

(2017) Sarah L. DeVos et al.   Science Translational Medicine

A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies

(2017) Miranda E. Orr et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target

(2017) B. Borroni et al.   Scientific Reports

Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria

(2017) Michael J. Strong et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

(2016) Mansi R. Khanna et al.   Alzheimers & Dementia

Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

(2016) Davide Seripa et al.   Expert Review of Neurotherapeutics

Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy

(2016) Francesco Panza et al.   Immunotherapy

Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association

(2016) Apostolos Papazacharias et al.   JOURNAL OF ALZHEIMERS DISEASE

Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update

(2016) Patrick Oeckl et al.   JOURNAL OF NEUROCHEMISTRY

Therapy and clinical trials in frontotemporal dementia: past, present, and future

(2016) Richard M. Tsai et al.   JOURNAL OF NEUROCHEMISTRY

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia

(2016) Christopher J. Holler et al.   Molecular Neurodegeneration

Agomelatine Improves Apathy in Frontotemporal Dementia

(2016) Ilaria Callegari et al.   Neurodegenerative Diseases

Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes

(2016) Ian T.S. Coyle-Gilchrist et al.   NEUROLOGY

Tauopathies as clinicopathological entities

(2016) David J. Irwin   PARKINSONISM & RELATED DISORDERS

Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts

(2016) N. J. Kramer et al.   SCIENCE

Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses

(2016) Katannya Kapeli et al.   Nature Communications

CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia

(2016) Kelly L. Williams et al.   Nature Communications

Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

(2016) Davide Seripa et al.   Expert Review of Neurotherapeutics

Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration

(2016) Ito Kawakami et al.   Acta Neuropathologica Communications

Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers

(2015) Ian R. A. Mackenzie et al.   ACTA NEUROPATHOLOGICA

Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease

(2015) Cyril Pottier et al.   ACTA NEUROPATHOLOGICA

Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with α7 nicotinic acetylcholine receptor agonists

(2015) S. Sakura Minami et al.   BIOCHEMICAL PHARMACOLOGY

Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia

(2015) Tobias Skillbäck et al.   BRAIN

Improving response inhibition systems in frontotemporal dementia with citalopram

(2015) Laura E. Hughes et al.   BRAIN

Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus

(2015) Jiaxin Hu et al.   CHEMISTRY & BIOLOGY

Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease

(2015) Francesco Panza et al.   EXPERT OPINION ON PHARMACOTHERAPY

A Case of Frontotemporal Dementia Presenting With Treatment-Refractory Psychosis and Extreme Violence

(2015) Manish Kumar Jha et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

(2015) N K Magdalinou et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease

(2015) Inês Baldeiras et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Frontotemporal dementia

(2015) Jee Bang et al.   LANCET

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

(2015) Sang-Won Min et al.   NATURE MEDICINE

Human secreted tau increases amyloid-beta production

(2015) Jessica Bright et al.   NEUROBIOLOGY OF AGING

Treatment with a Global Methyltransferase Inhibitor Induces the Intranuclear Aggregation of ALS-Linked FUS Mutant In Vitro

(2015) Sakiko Fujii et al.   NEUROCHEMICAL RESEARCH

Souvenaid Reduces Behavioral Deficits and Improves Social Cognition Skills in Frontotemporal Dementia: A Proof-of-Concept Study

(2015) Matteo Pardini et al.   Neurodegenerative Diseases

CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders

(2015) Megan K. Herbert et al.   Frontiers in Neurology

Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis

(2015) Hanne Struyfs et al.   Frontiers in Neurology

The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy

(2015) Robert Siman et al.   PLoS One

Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine

(2014) David J. Irwin et al.   ACTA NEUROPATHOLOGICA

A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement

(2014) Sylvie Bannwarth et al.   BRAIN

Hsp90-Tau Complex Reveals Molecular Basis for Specificity in Chaperone Action

(2014) G. Elif Karagöz et al.   CELL

Prion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target

(2014) Brandon B. Holmes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature

(2014) Wei Tang et al.   JOURNAL OF NEURAL TRANSMISSION

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies

(2014) Chun-ling Dai et al.   JOURNAL OF NEURAL TRANSMISSION

Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies

(2014) Wei Tang et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

(2014) Adam L Boxer et al.   LANCET NEUROLOGY

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

(2014) Eduardo Tolosa et al.   MOVEMENT DISORDERS

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial

(2014) Günter U. Höglinger et al.   MOVEMENT DISORDERS

Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation

(2014) A. Alberici et al.   NEUROLOGICAL SCIENCES

Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability

(2014) E. C. Finger et al.   NEUROLOGY

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

(2014) Eva Kontsekova et al.   Alzheimers Research & Therapy

Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia

(2014) Barbara Borroni et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies

(2014) Reeteka Sud et al.   Molecular Therapy-Nucleic Acids

Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72

(2014) Yvonne S Davidson et al.   Acta Neuropathologica Communications

Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins

(2013) Kohji Mori et al.   ACTA NEUROPATHOLOGICA

Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS

(2013) Tania F. Gendron et al.   ACTA NEUROPATHOLOGICA

A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

(2013) Bruce H. Morimoto et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Targeted manipulation of the sortilin–progranulin axis rescues progranulin haploinsufficiency

(2013) Wing C. Lee et al.   HUMAN MOLECULAR GENETICS

Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders

(2013) J. Janssens et al.   HUMAN MOLECULAR GENETICS

TARDBPandFUSMutations Associated with Amyotrophic Lateral Sclerosis: Summary and Update

(2013) Serena Lattante et al.   HUMAN MUTATION

Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial

(2013) Adam L Boxer et al.   LANCET NEUROLOGY

Tau pathology and neurodegeneration

(2013) Maria Grazia Spillantini et al.   LANCET NEUROLOGY

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transport

(2013) Yan Jouroukhin et al.   NEUROBIOLOGY OF DISEASE

Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP

(2013) W. T. Hu et al.   NEUROLOGY

Criteria for the diagnosis of corticobasal degeneration

(2013) M. J. Armstrong et al.   NEUROLOGY

Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS

(2013) Peter E.A. Ash et al.   NEURON

RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention

(2013) Christopher J. Donnelly et al.   NEURON

Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia

(2013) L Fredrik Jarskog et al.   NEUROPSYCHOPHARMACOLOGY

Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice

(2013) Sefika Ozcelik et al.   PLoS One

Increasing Brain Protein O-GlcNAc-ylation Mitigates Breathing Defects and Mortality of Tau.P301L Mice

(2013) Peter Borghgraef et al.   PLoS One

RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia

(2013) T. Zu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration

(2013) C. Lagier-Tourenne et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS

(2013) K. Mori et al.   SCIENCE

Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion

(2013) D. Sareen et al.   Science Translational Medicine

Propagation of tau pathology in Alzheimer’s disease: identification of novel therapeutic targets

(2013) Amy M Pooler et al.   Alzheimers Research & Therapy

Prion-like Properties of Pathological TDP-43 Aggregates from Diseased Brains

(2013) Takashi Nonaka et al.   Cell Reports

Development and Validation of Pedigree Classification Criteria for Frontotemporal Lobar Degeneration

(2013) Elisabeth M. Wood et al.   JAMA Neurology

Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations

(2012) Manuela Neumann et al.   ACTA NEUROPATHOLOGICA

The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)

(2012) Adam L. Boxer et al.   Alzheimers & Dementia

Degradation of tau protein by autophagy and proteasomal pathways: Figure 1

(2012) Yipeng Wang et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

(2012) Shiro Soga et al.   CURRENT PHARMACEUTICAL DESIGN

A Pan-European Study of theC9orf72Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats

(2012) Julie van der Zee et al.   HUMAN MUTATION

Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype

(2012) Matthis Synofzik et al.   NEUROBIOLOGY OF AGING

C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts

(2012) C. Dobson-Stone et al.   NEUROLOGY

Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies

(2011) Zeshan Ahmed et al.   ACTA NEUROPATHOLOGICA

Transportin1: a marker of FTLD-FUS

(2011) Jack Brelstaff et al.   ACTA NEUROPATHOLOGICA

Alzheimer’s pathogenesis: is there neuron-to-neuron propagation?

(2011) Heiko Braak et al.   ACTA NEUROPATHOLOGICA

Neuropathological background of phenotypical variability in frontotemporal dementia

(2011) Keith A. Josephs et al.   ACTA NEUROPATHOLOGICA

A harmonized classification system for FTLD-TDP pathology

(2011) Ian R. A. Mackenzie et al.   ACTA NEUROPATHOLOGICA

Serotonergic Function and Treatment of Behavioral and Psychological Symptoms of Frontotemporal Dementia

(2011) Nathan Herrmann et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

The effects of oxytocin on social cognition and behaviour in frontotemporal dementia

(2011) Sarah Jesso et al.   BRAIN

FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations

(2011) Manuela Neumann et al.   BRAIN

Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration

(2011) J. D. Rohrer et al.   BRAIN

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

(2011) Katya Rascovsky et al.   BRAIN

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

(2011) Argonde C. van Harten et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Frontotemporal Dementia Caused by CHMP2B Mutations

(2011) A. M. Isaacs et al.   Current Alzheimer Research

Phenotypic signatures of genetic frontotemporal dementia

(2011) Jonathan D. Rohrer et al.   CURRENT OPINION IN NEUROLOGY

Suberoylanilide Hydroxamic Acid (Vorinostat) Up-regulates Progranulin Transcription

(2011) Basar Cenik et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Rescue of Progranulin Deficiency Associated with Frontotemporal Lobar Degeneration by Alkalizing Reagents and Inhibition of Vacuolar ATPase

(2011) A. Capell et al.   JOURNAL OF NEUROSCIENCE

Classification of primary progressive aphasia and its variants

(2011) M. L. Gorno-Tempini et al.   NEUROLOGY

Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS

(2011) Mariely DeJesus-Hernandez et al.   NEURON

C-Terminus of Progranulin Interacts with the Beta-Propeller Region of Sortilin to Regulate Progranulin Trafficking

(2011) Yanqiu Zheng et al.   PLoS One

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia

(2011) Daniel C. Javitt et al.   SCHIZOPHRENIA RESEARCH

The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in Mice

(2011) W. Tang et al.   SCIENCE

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias

(2011) Ralf Ihl et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis

(2010) Brian C. Kraemer et al.   ACTA NEUROPATHOLOGICA

FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration

(2010) Hazel Urwin et al.   ACTA NEUROPATHOLOGICA

Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis

(2010) Iuga Liepelt et al.   Alzheimers & Dementia

Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia

(2010) J. Yan et al.   NEUROLOGY

Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin

(2010) Fenghua Hu et al.   NEURON

FUS pathology in basophilic inclusion body disease

(2009) David G. Munoz et al.   ACTA NEUROPATHOLOGICA

Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update

(2009) Ian R. A. Mackenzie et al.   ACTA NEUROPATHOLOGICA

TARDBPmutations in motoneuron disease with frontotemporal lobar degeneration

(2009) Lina Benajiba et al.   ANNALS OF NEUROLOGY

Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members

(2009) N. Finch et al.   BRAIN

A new subtype of frontotemporal lobar degeneration with FUS pathology

(2009) M. Neumann et al.   BRAIN

Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease

(2009) F. Liu et al.   BRAIN

Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models

(2009) Makiko Yamashita et al.   FEBS LETTERS

Stimulant Treatment of Frontotemporal Dementia in 8 Patients

(2009) Edward D. Huey et al.   JOURNAL OF CLINICAL PSYCHIATRY

Behavioural abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline

(2009) C I Prodan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

"Frontotemporoparietal" dementia: Clinical phenotype associated with the c.709-1G>A PGRN mutation

(2009) F. Moreno et al.   NEUROLOGY

The heritability and genetics of frontotemporal lobar degeneration

(2009) J. D. Rohrer et al.   NEUROLOGY

Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6

(2009) C. Vance et al.   SCIENCE

Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis

(2009) T. J. Kwiatkowski et al.   SCIENCE

Frontotemporal dementia and related disorders: Deciphering the enigma

(2008) Keith A. Josephs   ANNALS OF NEUROLOGY

The Natively Unfolded Character of Tau and Its Aggregation to Alzheimer-like Paired Helical Filaments†

(2008) Sadasivam Jeganathan et al.   BIOCHEMISTRY

Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions

(2008) Ian R. A. Mackenzie et al.   BRAIN

Galantamine in Frontotemporal Dementia and Primary Progressive Aphasia

(2008) A. Kertesz et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival

(2008) Philip Van Damme et al.   JOURNAL OF CELL BIOLOGY

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

(2008) Y. Matsuoka et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration

(2008) R. Ghidoni et al.   NEUROLOGY